Vanessa 
Patients in England battling advanced melanoma will soon gain access to a groundbreaking cancer vaccine. This opportunity comes as the NHS extends its innovative Cancer Vaccine Launch Pad.
Melanoma is the fifth most common cancer in the UK, accounting for nearly 4% of new diagnoses. According to Cancer Research UK, melanoma cases rose by 33% between 2009 and 2019. As a result, the demand for more effective treatments continues to grow.
How the iSCIB1+ Vaccine Works
The new vaccine, iSCIB1+, is a DNA-based, needle-free treatment designed to enhance the immune system. It trains the body to recognise and attack cancer cells, which helps prevent the disease from returning.
Unlike personalised vaccines, iSCIB1+ is not tailored to an individual’s tumour. Even so, it significantly boosts the response to immunotherapy. Patients will receive it over a two-year period. Consequently, the vaccine could reduce the risk of relapse for many.
Wider Access Through NHS Partnership with Scancell
To support the rollout, the NHS partnered with British biotech firm Scancell. Initially, seven hospitals in England will offer the vaccine. However, more facilities are expected to join the programme soon. The first group of patients will start treatment in May 2025.
This vaccine is part of the Cancer Vaccine Launch Pad (CVLP), a world-first initiative aimed at speeding up access to clinical trials. The ongoing phase two trial, called SCOPE, already includes participants. Moreover, dozens of additional patients are expected to join by October.
Experts Optimistic About Long-Term Impact
Professor Peter Johnson, NHS England’s National Cancer Director, shared his excitement about the progress. “Skin cancer can be devastating,” he said. “But cancer vaccines like this could completely change the way we treat patients, not just in the UK, but globally.”
He also stressed the importance of rapid access. “We’re working with industry partners to ensure eligible patients are quickly connected to these potentially life-saving trials,” he added.
Overall, the expansion of this programme marks a promising step forward. With continued support and access, the iSCIB1+ vaccine could play a vital role in preventing cancer recurrence and saving lives.
